UA41995C2
(uk)
*
|
1994-05-06 |
2001-10-15 |
Пфайзер Інк. |
Лікарська форма азитроміцину з контрольованим вивільненням ( варіанти ), спосіб її введення, спосіб її виготовлення і спосіб лікування інфекційних захворювань ссавців з її використанням ( варіанти )
|
TW487582B
(en)
*
|
1995-08-11 |
2002-05-21 |
Nissan Chemical Ind Ltd |
Method for converting sparingly water-soluble medical substance to amorphous state
|
US20050064033A1
(en)
*
|
1997-04-11 |
2005-03-24 |
Notario Gerard F. |
Extended release formulations of erythromycin derivatives
|
US6551616B1
(en)
*
|
1997-04-11 |
2003-04-22 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
US6010718A
(en)
*
|
1997-04-11 |
2000-01-04 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
SI20108B
(en)
*
|
1997-06-11 |
2001-12-31 |
Abbott Lab |
A controlled release formulation for poorly soluble basic drugs
|
US6156771A
(en)
*
|
1997-08-28 |
2000-12-05 |
Rubin; Walter |
Method for alleviation of lower gastrointestinal disorders in a human patient
|
WO1999049863A1
(fr)
*
|
1998-03-26 |
1999-10-07 |
Fujisawa Pharmaceutical Co., Ltd. |
Preparations a liberation prolongee
|
EE05054B1
(et)
*
|
1998-08-21 |
2008-08-15 |
Novartis Ag |
5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
|
IT1313610B1
(it)
|
1999-08-09 |
2002-09-09 |
S I F I Societa Ind Farmaceuti |
Processo per la preparazione di formulazioni acquose per uso oftalmico
|
TR200000054A2
(tr)
*
|
2000-01-05 |
2001-08-21 |
Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ |
Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6565882B2
(en)
*
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
CZ20023167A3
(cs)
*
|
2000-02-29 |
2003-10-15 |
Teva Pharmaceutical Industries Ltd. |
Způsob přípravy klaritromycinu a klaritromycinového meziproduktu, v podstatě prostého oximu a farmaceutický prostředek, který jej obsahuje
|
AU2001263812B2
(en)
*
|
2000-03-28 |
2004-09-23 |
Sandoz Ag |
Granulated particles with masked taste
|
DE10031043A1
(de)
*
|
2000-06-26 |
2002-02-14 |
Bayer Ag |
Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
|
IN192748B
(de)
*
|
2000-08-29 |
2004-05-15 |
Ranbaxy Lab Ltd |
|
US6541014B2
(en)
*
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
US20020068078A1
(en)
*
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
US20020197314A1
(en)
*
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
US6673369B2
(en)
|
2001-08-29 |
2004-01-06 |
Ranbaxy Laboratories Limited |
Controlled release formulation
|
HUP0500791A2
(en)
*
|
2001-08-29 |
2006-09-28 |
Ranbaxy Lab Ltd |
Controlled release formulation of clarithromycin or tinidazol
|
US6642276B2
(en)
*
|
2001-10-01 |
2003-11-04 |
M/S Ind-Swift Limited |
Controlled release macrolide pharmaceutical formulations
|
US20030091627A1
(en)
*
|
2001-10-31 |
2003-05-15 |
Vinay Sharma |
Rate-controlled delivery of macrolides
|
US7037523B2
(en)
*
|
2001-11-02 |
2006-05-02 |
Wockhardt Limited |
Controlled release compositions for macrolide antimicrobial agents
|
US20030181488A1
(en)
*
|
2002-03-07 |
2003-09-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
|
EP1485078B1
(de)
*
|
2002-03-15 |
2012-09-26 |
Cypress Bioscience, Inc. |
Milnacipran zur Behandlung von Reizdarmsyndrom
|
AU2003245504A1
(en)
*
|
2002-06-14 |
2003-12-31 |
Andrx Corporation |
Pharmaceutical compositions for drugs having ph-dependentsolubility
|
US20060083759A1
(en)
*
|
2002-07-17 |
2006-04-20 |
Aleksander Resman |
Stabilization of the profile of release of active substances from a formulation
|
SI21300A
(sl)
*
|
2002-10-08 |
2004-04-30 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Farmacevtske formulacije z alginati
|
US20040132826A1
(en)
*
|
2002-10-25 |
2004-07-08 |
Collegium Pharmaceutical, Inc. |
Modified release compositions of milnacipran
|
US20060003004A1
(en)
*
|
2002-10-25 |
2006-01-05 |
Collegium Pharmaceutical, Inc. |
Pulsatile release compositions of milnacipran
|
GB0230034D0
(en)
*
|
2002-12-23 |
2003-01-29 |
Biochemie Gmbh |
Organic compounds
|
AU2004207578B2
(en)
*
|
2003-01-28 |
2007-06-28 |
Collegium Pharmaceutical, Inc. |
Multiparticulate compositions of milnacipran for oral administration
|
US20040185097A1
(en)
*
|
2003-01-31 |
2004-09-23 |
Glenmark Pharmaceuticals Ltd. |
Controlled release modifying complex and pharmaceutical compositions thereof
|
NZ543395A
(en)
*
|
2003-05-06 |
2008-04-30 |
Nirmal Mulye |
Controlled release formulation of erythromycin derivatives
|
US7063862B2
(en)
*
|
2003-06-03 |
2006-06-20 |
Biokey, Inc. |
Pharmaceutical composition and method for treating
|
CA2675724C
(en)
*
|
2003-06-16 |
2012-12-04 |
Andrx Pharmaceuticals, Llc |
Oral extended-release composition
|
US20050053658A1
(en)
*
|
2003-09-09 |
2005-03-10 |
Venkatesh Gopi M. |
Extended release systems for macrolide antibiotics
|
US8313776B2
(en)
*
|
2003-07-21 |
2012-11-20 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
JP2006528185A
(ja)
*
|
2003-07-21 |
2006-12-14 |
アドバンシス ファーマスーティカル コーポレイション |
抗生物質製剤、その使用法及び作成方法
|
US8313775B2
(en)
*
|
2003-07-21 |
2012-11-20 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
WO2005016311A1
(en)
*
|
2003-08-11 |
2005-02-24 |
Advancis Pharmaceutical Corporation |
Robust pellet
|
JP2007502294A
(ja)
*
|
2003-08-12 |
2007-02-08 |
アドバンシス ファーマスーティカル コーポレイション |
抗生物質製剤、その使用法及び作成方法
|
EP1658034A4
(de)
*
|
2003-08-29 |
2011-06-22 |
Middlebrook Pharmaceuticals Inc |
Antibiotisches produkt, seine verwendung und formulierung
|
JP2007513869A
(ja)
*
|
2003-09-15 |
2007-05-31 |
アドバンシス ファーマスーティカル コーポレイション |
抗生物質製剤、その使用法及び作成方法
|
CA2540104A1
(en)
*
|
2003-09-30 |
2005-04-07 |
Solubest Ltd. |
Water soluble nanoparticles comprising inclusion complexes
|
RU2006119453A
(ru)
*
|
2003-12-04 |
2007-12-20 |
Пфайзер Продактс Инк. (Us) |
Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц
|
WO2005053639A2
(en)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Controlled release multiparticulates formed with dissolution enhancers
|
WO2005053656A1
(en)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
|
WO2005053651A1
(en)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Multiparticulate compositions with improved stability
|
WO2005053652A1
(en)
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
|
US6984403B2
(en)
*
|
2003-12-04 |
2006-01-10 |
Pfizer Inc. |
Azithromycin dosage forms with reduced side effects
|
CA2547773A1
(en)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
|
WO2005053655A1
(en)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Method for making pharmaceutical multiparticulates
|
WO2005062898A2
(en)
*
|
2003-12-24 |
2005-07-14 |
Advancis Pharmaceutical Corporation |
Enhanced absorption of modified release dosage forms
|
CN100435847C
(zh)
*
|
2004-05-13 |
2008-11-26 |
宝龄富锦生技股份有限公司 |
含有难溶解性主药之持续释放配方
|
US20050260263A1
(en)
*
|
2004-05-18 |
2005-11-24 |
Panion & Bf Biotech Inc. |
Sustained release formulation for sparingly soluble main drugs
|
CA2572223C
(en)
|
2004-06-25 |
2014-08-12 |
The Johns Hopkins University |
Angiogenesis inhibitors
|
JP2008505124A
(ja)
*
|
2004-07-02 |
2008-02-21 |
アドバンシス ファーマスーティカル コーポレイション |
パルス送達用錠剤
|
CN1322866C
(zh)
*
|
2004-10-12 |
2007-06-27 |
广州贝氏药业有限公司 |
一种多单元缓释制剂
|
DE102005042875A1
(de)
*
|
2004-12-23 |
2006-09-21 |
Grünenthal GmbH |
Schnell freisetzende Darreichungsformen für Antibiotika
|
US20070015719A1
(en)
*
|
2005-07-07 |
2007-01-18 |
Elan Pharma International Limited |
Nanoparticulate clarithromycin formulations
|
US20070128272A1
(en)
*
|
2005-12-07 |
2007-06-07 |
Zerbe Horst G |
Multi-vitamin and mineral supplement
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
US8778924B2
(en)
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
BRPI0707324A2
(pt)
*
|
2006-01-27 |
2011-05-03 |
Eurand Inc |
sistemas de fornecimento de fármaco compreendendo agente de bloqueio de serotonina 5-ht3 seletivo fracamente básico e ácidos orgánicos
|
NZ569984A
(en)
*
|
2006-01-27 |
2011-06-30 |
Eurand Inc |
Drug delivery systems comprising weakly basic drugs and organic acids
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
EP2030613A1
(de)
*
|
2007-08-17 |
2009-03-04 |
Abbott GmbH & Co. KG |
Herstellung von Zusammensetzungen mit hauptsächlich nichtkristallinen eingebetteten Makrolid-Antibiotika
|
PT2234607E
(pt)
*
|
2007-12-28 |
2011-09-30 |
Acraf |
Formulação de libertação lenta com base numa associação de glicogénio e alginato
|
US8133506B2
(en)
*
|
2008-03-12 |
2012-03-13 |
Aptalis Pharmatech, Inc. |
Drug delivery systems comprising weakly basic drugs and organic acids
|
US8729097B2
(en)
|
2008-10-06 |
2014-05-20 |
The Johns Hopkins University |
Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders
|
WO2010138054A1
(en)
*
|
2009-05-29 |
2010-12-02 |
Tetra Laval Holdings & Finance S.A. |
Packaging material comprising magnetisable portions
|
US20110003005A1
(en)
*
|
2009-07-06 |
2011-01-06 |
Gopi Venkatesh |
Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
|
EP2451444A1
(de)
*
|
2009-07-07 |
2012-05-16 |
Sunovion Pharmaceuticals Inc. |
Formulierungen von 6- (5-chloro-2-pyridyl) - 5- [ (4-methyl-1-piperazinyl) carbonyloxy]- 7-0x0-6, 7- dihydro- 5h- phyrrolo [3, 4-b]pyrazin
|
EP2283824B1
(de)
|
2009-07-30 |
2017-04-19 |
Special Products Line S.p.A. |
Zusammensetzungen und Formulierungen, die auf quellbaren Matrizen basieren, zur verzögerten Freisetzung von schlecht löslichen Arzneimitteln, wie zum Beispiel Clarithromycin
|
WO2011026234A1
(en)
*
|
2009-09-02 |
2011-03-10 |
Bernard Charles Sherman |
Clarithromycin extended-release tablet
|
CN102106807B
(zh)
|
2009-12-29 |
2013-03-27 |
上海中西制药有限公司 |
一种固体制剂的制备方法及所得固体制剂
|
US9011912B2
(en)
|
2010-10-07 |
2015-04-21 |
Abon Pharmaceuticals, Llc |
Extended-release oral dosage forms for poorly soluble amine drugs
|
WO2012083017A2
(en)
|
2010-12-16 |
2012-06-21 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
US9532977B2
(en)
|
2010-12-16 |
2017-01-03 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
DE102013202703B4
(de)
|
2013-02-20 |
2020-03-12 |
Siemens Healthcare Gmbh |
Vorrichtung und Verfahren zur Kollisionserkennung bei einem medizintechnischen Gerät
|
BR112015025460B1
(pt)
|
2013-04-07 |
2024-01-02 |
The Broad Institute, Inc. |
Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
CA2934073A1
(en)
|
2013-12-20 |
2015-06-25 |
The Broad Institute, Inc. |
Combination therapy with neoantigen vaccine
|
EP3234193B1
(de)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molekulare biomarker für krebsimmuntherapie
|
EP3757211A1
(de)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Verfahren zur profilierung des t-zell-rezeptor-repertoirs
|
RU2020132040A
(ru)
|
2015-05-20 |
2020-10-12 |
Те Брод Инститьют Инк. |
Общие неоантигены
|
WO2017027778A1
(en)
*
|
2015-08-13 |
2017-02-16 |
Temple University-Of The Commonwealth System Of Higher Education |
Calcium alginate dosage formulations, and methods of making and using thereof
|
EP3373916A1
(de)
|
2015-11-11 |
2018-09-19 |
Celgene Corporation |
Orale retard-darreichungsformen von schwer löslichen arzneimitteln und verwendungen davon
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
WO2018140391A1
(en)
|
2017-01-24 |
2018-08-02 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
WO2018207188A1
(en)
*
|
2017-05-11 |
2018-11-15 |
Steadymed, Ltd. |
Enhanced solubility drug-containing formulations
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
CN111184699A
(zh)
*
|
2020-04-09 |
2020-05-22 |
河北大学 |
一种硝苯地平控释胶囊及其制备方法
|
KR20230029673A
(ko)
|
2020-05-26 |
2023-03-03 |
디오니스 테라퓨틱스, 아이엔씨. |
핵산 인공 미니-프로테옴 라이브러리
|
WO2023076733A1
(en)
|
2021-11-01 |
2023-05-04 |
Dana-Farber Cancer Institute, Inc. |
Biologically selected nucleic acid artificial mini-proteome libraries
|